Serum immunoglobulin levels in group E of chronic obstructive pulmonary disease: insights for clinical management and immunoglobulin therapy strategies.
COPD
CVID
IVIG
Immunoglobulin defficiency
Immunoglobulin therapy
Journal
BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563
Informations de publication
Date de publication:
02 Aug 2024
02 Aug 2024
Historique:
received:
17
03
2024
accepted:
25
07
2024
medline:
3
8
2024
pubmed:
3
8
2024
entrez:
2
8
2024
Statut:
epublish
Résumé
The study aimed to characterize serum immunoglobulin (Ig) concentrations and their relationship with clinical and paraclinical features in patients with COPD group E in the stable stage. Additionally, the study focused on evaluating the relationship between serum Ig levels and the risk of exacerbations over the next 12 months, thereby clarifying the role of serum Ig deficiency in affecting the future risk for these patients. A prospective observational study assessed IgG, IgA, IgM, and IgE levels in 67 COPD patients and 30 healthy controls at Military Hospital 103 from October 2017 to August 2020. Primary outcomes included Ig isotype levels in COPD patients, with secondary outcomes exploring differences compared to controls and associations with clinical variables. COPD patients showed significantly lower IgG concentrations and higher IgA levels than controls. IgM and IgE levels did not differ significantly. Subgroup analysis revealed notable decreases in IgG1 and IgG3 concentrations, with 10.4% of patients exhibiting reduced IgG levels and 0.3% diagnosed with common variable immunodeficiency. No significant associations were found between Ig levels and exacerbation risk or clinical variables. Serum IgG and IgM concentrations were significantly reduced in COPD patients compared to normal individuals, with IgG1 and IgG3 concentrations notably low. Serum IgA levels were significantly higher in COPD patients compared with normal controls. However, no significant association was found between Ig concentrations, particularly serum IgG deficiency and its subclasses, with the frequency and risk of exacerbations during 12 months of longitudinal follow-up. Caution is warranted in the use of immunoglobulin therapy in the treatment of COPD patients. An independent ethics committee approved the study (Ethics Committee of Military Hospital 103 (No. 57/2014/VMMU-IRB), which was performed in accordance with the Declaration of Helsinki, Guidelines for Good Clinical Practice.
Identifiants
pubmed: 39095819
doi: 10.1186/s12890-024-03185-5
pii: 10.1186/s12890-024-03185-5
doi:
Substances chimiques
Immunoglobulin G
0
Immunoglobulin A
0
Immunoglobulins
0
Immunoglobulin M
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
381Informations de copyright
© 2024. The Author(s).
Références
2023 GOLD Report. Global Initiative for Chronic Obstructive Lung Disease - GOLD, https://goldcopd.org/2023-gold-report-2/ , accessed: 05/15/2023.
Tanimura K, Sato S, Sato A et al. (2020). Low serum free light chain is associated with risk of COPD exacerbation. ERJ Open Res, 6(2).
Putcha N, Paul GG, Azar A et al. (2018). Lower serum IgA is associated with COPD exacerbation risk in SPIROMICS. PLoS ONE, 13(4), e0194924.
Braber S, Thio M, Blokhuis BR, et al. An association between neutrophils and immunoglobulin free light chains in the pathogenesis of COPD. Am J Respir Crit Care Med. 2012;185(8):817–24.
doi: 10.1164/rccm.201104-0761OC
pubmed: 22227380
McCullagh BN, Comellas AP, Ballas ZK et al. (2017). Antibody deficiency in patients with frequent exacerbations of COPD (COPD). PLoS ONE, 12(2).
Bonilla FA, Bernstein IL, Khan DA, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol off Publ Am Coll Allergy Asthma Immunol. 2005;94(5 Suppl 1):S1–63.
Holma P, Pesonen P, Karjalainen MK et al. (2023). Low and high serum IgG associates with respiratory infections in a young and working age population. eBioMedicine, 94.
Ghafoor A, Joseph SM. Making a diagnosis of CVID: a review. Cureus, 12(1), e6711.
Hartung H-P, Mouthon L, Ahmed R, et al. Clinical applications of intravenous immunoglobulins (IVIg)--beyond immunodeficiencies and neurology. Clin Exp Immunol. 2009;158(1Suppl 1):23–33.
doi: 10.1111/j.1365-2249.2009.04024.x
pubmed: 19883421
pmcid: 2801038
Leitao Filho FS, Mattman A, Schellenberg R, et al. Serum IgG levels and risk of COPD hospitalization: a pooled Meta-analysis. Chest. 2020;158(4):1420–30.
doi: 10.1016/j.chest.2020.04.058
pubmed: 32439504
Cowan J, Gaudet L, Mulpuru S et al. (2015). A retrospective longitudinal within-subject risk interval analysis of Immunoglobulin Treatment for recurrent Acute Exacerbation of COPD. PLoS ONE, 10(11).
Wen L, Krauss-Etschmann S, Petersen F et al. (2018). Autoantibodies in COPD. Front Immunol, 9.
GOLD 2017 Global Strategy for the Diagnosis, Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease - GOLD, http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/ , accessed: 07/25/2017.
Furst DE. Serum immunoglobulins and risk of infection: how low can you go? Semin Arthritis Rheum. 2009;39(1):18–29.
doi: 10.1016/j.semarthrit.2008.05.002
pubmed: 18620738
Gathmann B, Mahlaoui N, CEREDIH, et al. Clinical picture and treatment of 2212 patients with CVID. J Allergy Clin Immunol. 2014;134(1):116–26.
doi: 10.1016/j.jaci.2013.12.1077
pubmed: 24582312
Palikhe NS, Niven M, Fuhr D, et al. Low immunoglobulin levels affect the course of COPD in hospitalized patients. Allergy Asthma Clin Immunol. 2023;19(1):10.
doi: 10.1186/s13223-023-00762-x
pubmed: 36710354
pmcid: 9885564
Gonzalez-Quintela A, Alende R, Gude F, et al. Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities. Clin Exp Immunol. 2008;151(1):42–50.
doi: 10.1111/j.1365-2249.2007.03545.x
pubmed: 18005364
pmcid: 2276914
Williamson Mary A, Snyder LM. (2014), Wallach’s Interpretation Of Diagnostic Tests, 10 E 2014 [PDF] [Dr. Carson] VRG.
Kim J-H, Park S, Hwang YI, et al. Immunoglobulin G Subclass Deficiencies in adult patients with chronic Airway diseases. J Korean Med Sci. 2016;31(10):1560–5.
doi: 10.3346/jkms.2016.31.10.1560
pubmed: 27550483
pmcid: 4999397
Samea ERA, Al Baiomy A, El-Desoky M et al. Value of Serum ECP and IgE in Differentiation between Asthma and COPD.
Holm AM, Andreassen SL, Christensen VL, et al. Hypogammaglobulinemia and risk of exacerbation and mortality in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2020;15:799–807.
doi: 10.2147/COPD.S236656
pubmed: 32368026
pmcid: 7173948
Picard C, Al-Herz W, Bousfiha A, et al. Primary Immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for primary immunodeficiency 2015. J Clin Immunol. 2015;35(8):696–726.
doi: 10.1007/s10875-015-0201-1
pubmed: 26482257
pmcid: 4659841
Leitao Filho FS, Ra SW, Mattman A et al. (2018). Serum IgG subclass levels and risk of exacerbations and hospitalizations in patients with COPD. Respir Res, 19.
Bermejo-Martín JF, Rodriguez-Fernandez A, Herrán-Monge R, et al. Immunoglobulins IgG1, IgM and IgA: a synergistic team influencing survival in sepsis. J Intern Med. 2014;276(4):404–12.
doi: 10.1111/joim.12265
pubmed: 24815605
Unninayar D, Shea B, Cameron DW et al. (2023). Levels of immunoglobulin isotypes in serum and respiratory samples of patients with COPD: protocol for a systematic review and meta-analysis. BMJ Open, 13(2), e064307.
Ba Ta T, Tran Viet T, Xuan Nguyen K, et al. Changes in serum immunoglobulin G subclasses during the treatment of patients with COPD with infectious exacerbations. Adv Respir Med. 2022;90(6):500–10.
doi: 10.3390/arm90060056
pubmed: 36547011
pmcid: 9774113
Cowan J, Mulpuru S, Alvarez G, et al. COPD exacerbation frequency and serum IgG levels. J Allergy Clin Immunol. 2018;141(2):830–1.
doi: 10.1016/j.jaci.2017.09.036
pubmed: 29221818